10-Q · May 7, 2026
Lipocine reported a revenue increase to $119,397 in Q1 2026, up from $93,864 in Q1 2025, alongside gross margins remaining at 100%. The company recorded a diluted EPS of -0.53, a decrease from -0.35 in the prior year.…
Earnings analysis · 10-Q
LPCN earnings analysis
Filed August 4, 2026 · Our reading of the company's report
The latest report
Lipocine’s Q2 revenue declined 69.5% year over year to $190,099 as the prior-year licensing contribution did not recur; the filing does not disclose quarterly EPS, gross margin, segment revenue, or free cash flow.…
Read full summary
Lipocine’s Q2 revenue declined 69.5% year over year to $190,099 as the prior-year licensing contribution did not recur; the filing does not disclose quarterly EPS, gross margin, segment revenue, or free cash flow. Six-month operating cash use rose to $5.29 million, but an ATM raise lifted liquidity to $23.3 million and management projects runway through at least August 4, 2027. The central fundamental overhang remains LPCN 1154’s Phase 3 primary-endpoint miss, notwithstanding management’s post-hoc outlier-site analysis, planned FDA meeting, and newly initiated confirmatory PPD study.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
TLANDO royalty revenue of $190,099
Second-quarter revenue was $190,099, entirely TLANDO royalty revenue, versus $622,849 a year earlier, a $432,750 (69.5%) decline. The prior-year quarter included $500,000 of licensing revenue plus $123,000 of royalties, while 2026 revenue consisted only of royalties.
-
Liquidity rises to $23.3 million
Cash, cash equivalents and marketable investment securities increased to $23.3 million at June 30, 2026 from $14.9 million at December 31, 2025. The increase was primarily supported by $13.5 million of net ATM-equity proceeds from 2,083,276 shares sold at a $6.67 weighted-average price.
-
Quarterly R&D modestly lower
Quarterly R&D expense decreased $95,380 year over year to $2.04 million, while G&A rose $100,523 to $0.99 million. Management attributed the R&D decrease to approximately $96,000 lower miscellaneous development costs, with minimal change in LPCN 1154 spending.
-
TLANDO receives UAE authorization
Pharmalink received UAE marketing authorization for TESTYRA (TLANDO) on July 8, 2026. Lipocine may receive regulatory milestones and supply-product revenue under the agreement, although the filing does not quantify the potential payment.
-
LPCN 1154 follow-up study initiated
Management plans an FDA guidance meeting in the third quarter of 2026 and has initiated a new placebo-controlled PPD study for LPCN 1154. In the post-hoc nonoutlier-site analysis (N=60), the hour-60 placebo-adjusted HAM-D difference was -5.8 (P<0.05), versus -1.3 and not statistically significant in the overall population (N=90).
What to watch
-
Phase 3 PPD primary endpoint was missed
LPCN 1154 failed its Phase 3 primary endpoint: in the full analysis set of N=90, the hour-60 placebo-adjusted HAM-D difference was -1.3 and not statistically significant. Management has begun another placebo-controlled study and scheduled an FDA meeting for Q3 2026, creating additional cost, timing and regulatory uncertainty.
-
Operating cash burn and future financing need
Cash used in operations increased 37.1% to $5.29 million for the first six months of 2026 from $3.86 million a year earlier, principally for LPCN 1154 trial activities. Management expects capital to last only through at least August 4, 2027 and says it will need additional capital after that date.
-
Accumulated deficit and equity dilution
The updated risk factors report an accumulated deficit of $215.7 million as of June 30, 2026 and state that losses are expected for the foreseeable future. The company raised $13.5 million through its ATM in the first half by issuing 2,083,276 shares, underscoring dilution risk.
-
Updated share-price volatility risk
The filing adds/updates common-stock volatility risk: shares traded between $1.94 and $11.26 during the 12 months ended June 30, 2026. This range may constrain the company’s ability to use its $50.0 million registered ATM capacity on attractive terms.
Management's outlook
No earnings or revenue guidance was provided. Liquidity outlook states that $23.3 million of unrestricted cash, cash equivalents and marketable securities is expected to fund projected operating requirements through at least August 4, 2027; management says additional capital will be required after that date.
Earlier filings 4
10-K · March 10, 2026
Lipocine’s 2025 10-K centers on monetizing its TLANDO franchise via multiple license agreements while advancing a pipeline of oral neuroactive steroid (NAS) candidates, notably LPCN 1154 for postpartum depression. The…
10-Q · May 8, 2025
Lipocine reported revenue of $93,864 for Q1 2025 (royalties) versus $7,617,174 in Q1 2024, producing a net loss of $(1,864,873) or $(0.35) per share. Operating expenses were $2,184,048, driving an operating loss of…
10-K · March 13, 2025
Lipocine is advancing its Lip’ral oral delivery platform while monetizing TLANDO through licenses (Verity, SPC, Pharmalink) and progressing CNS pipeline assets. The company received meaningful upfront/license payments…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.